EXCHANGE-2: Investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock – a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial
Authors: David Sascha , Bode Christian , Stahl Klaus 
Published: April 2023

Abstract
Background
Sepsis is as a life-threatening organ dysfunction caused by a dysregulated host response to an infection. The mortality of sepsis and particular of septic shock is very high. Treatment mostly focuses on infection control but a specific intervention that targets the underlying pathological host response is lacking to the present time.
The investigators hypothesize that early therapeutic plasma exchange (TPE) will dampen the maladaptive host response by removing injurious mediators thereby limiting organ dysfunction and improving survival in patients with septic shock. Although small prospective studies demonstrated rapid hemodynamic stabilization under TPE, no adequately powered randomized clinical trial has investigated hard outcomes.
Methods
This is a randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of TPE in patients with early septic shock. Patients with a refractory (defined as norepinephrine (NE) ≥ 0.4 μg/kg/min ≥ 30 min OR NE 0.3 μg/kg/min + vasopressin) and early (shock onset < 24h) septic shock will be included. The intervention is a standard TPE with donor fresh frozen plasma (1.2x individual plasma volume) performed within 6 hrs after randomization and will be compared to a standard of care (SOC) control arm. The primary endpoint is 28- days mortality for which the power analysis revealed a group size of 137 / arm (n=274) to demonstrate a benefit of 15%. The key secondary objective will be to compare the extent of organ failure indicated by mean SOFA over the first seven days as well as organ support free days until day 28 following randomization. Besides numerous biological secondary, safety endpoints such as incidence of bleeding, allergic reactions, transfusion associated lung injury, severe thrombocytopenia and other severe adverse events will be assessed during the first 7 days. For exploratory scientific analyses, biomaterial will be acquired longitudinally and multiple pre-defined scientific subprojects are planned. This study is an investigator-initiated trial supported by the German Research Foundation (DFG, DA 1209/7-1), in which 26 different centers in Germany, Switzerland and Austria will participate over a duration of 33 months.
Discussion
This trial has substantial clinical relevance as it evaluates a promising adjunctive treatment option in refractory septic shock patients suffering from an extraordinary high mortality. A positive trial result could change the current standard of care for this septic subgroup. The results of this study will be disseminated through presentations at international congresses, workshops, and peer-reviewed publications.
Trial Registration: ClinicalTrials.gov, NCT05726825, Registered on 02/14/2023, URL: https://clinicaltrials.gov/ct2/show/NCT05726825?term=NCT05726825&draw=2&rank=1
Trial Status
The current version of the study protocol described in the manuscript is Version 1.2, January 2023. The trial was registered at ClinicalTrials.gov (NCT05726825, date of registration: February 14th 2023, last update: February 14th 2023). No patient has yet been recruited. Anticipated start of trial recruitment will be in June 2023. Approximate end of recruitment will be May 2025.